Improved glycemic control in 3,592 adults with type 2 diabetes mellitus initiating a tubeless insulin management system

•There have been few studies of insulin pump therapy in people with T2DM.•HbA1c was lower 90 days after initiating Omnipod insulin pump in those with T2DM.•Total daily dose of insulin was lower 90 days after initiating Omnipod.•The frequency of hypoglycemic episodes was also lower after initiating Omnipod. To compare glycemic outcomes in adults with type 2 diabetes mellitus (T2DM) before and 90 days after initiating Omnipod® or Omnipod DASH® Insulin Management Systems. In this retrospective observational study (N = 3,592) change in HbA1c level, total daily dose (TDD) of insulin (n = 3,053), and frequency of self-reported hypoglycemic events (HE,